Genalyte to Use $44M Funding Round to Pursue FDA Clearance for Multiplexed Immunoassay Device | GenomeWeb

NEW YORK (GenomeWeb) – Having recently closed a $44 million Series C financing round, biotech firm Genalyte aims to use the funds to develop its Maverick biosensor system for rapid, routine testing in doctors' offices.

The San Diego-based company is preparing a clinical study through which it will collect data it will use to submit the device to the US Food and Drug Administration for 510(k) clearance in 2016, Cary Gunn, Genalyte's founder, president, and CEO, told GenomeWeb.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.